EUVIMEDEUVIMED entdecken
Crossref

Long-term effect of intravitreal dexamethasone implant (Ozurdex) in the treatment of resistant diabetic macular edema

AbdelrahmanG Salman

Journal of the Egyptian Ophthalmological Society · 2013

DOI: 10.4103/2090-0686.127404 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the Egyptian Ophthalmological Society, 2013. Verfasst von AbdelrahmanG Salman.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To evaluate the long-term safety and efficacy of Ozurdex in patients with resistant diabetic macular edema.

Design

A comparative, randomized, prospective, interventional case series. Patients and methods Fifteen patients with bilateral resistant diabetic macular edema were enrolled in this study. Eyes were randomized into right eyes that received intravitreal dexamethasone implant 0.7 mg (Ozurdex) and left eyes that received intravitreal bevacizumab injection 1.25 mg/0.05 ml. Outcome measures included the change in the best-corrected visual acuity (BCVA), the central macular thickness (CMT) on optical coherence tomography, and the intraocular pressure at 6 and 12 months after injection. Repeated injections were given in both groups when needed.

Results

The mean age of patients was 52.7 ± 2.1 years. The mean duration of diabetes mellitus was 15.2 years. In the Ozurdex group, the preoperative mean CMT was 535.2 μm, which improved to 198 and 230 μm at 6 and 12 months, respectively, and the preoperative mean BCVA was 0.80 log MAR units, which improved to 0.30 and 0.40 log MAR units at 6 and 12 months, respectively, with mean number of injections of 1.8 (range, 1-3) over 1 year. The intravitreal bevacizumab injection group improved from a mean preoperative CMT of 562.4 to 212 and 266 μm at 6 and 12 months, respectively, and the preoperative mean BCVA was 0.70 log MAR units, which improved to 0.30 and 0.40 log MAR units at 6 and 12 months, respectively, with mean number of injections of 5.4 (range, 4-8) over 1 year.

Conclusion

Ozurdex is an effective and safe alternative tool in the management of resistant diabetic macular edema. It can be considered as an off-label treatment with less frequent injection than intravitreal bevacizumab injection. Larger multicenter studies with a longer follow-up period are required.

Zitieren

APA

Salman, A. (2013). Long-term effect of intravitreal dexamethasone implant (Ozurdex) in the treatment of resistant diabetic macular edema. Journal of the Egyptian Ophthalmological Society. https://doi.org/10.4103/2090-0686.127404

Vancouver

Salman A. Long-term effect of intravitreal dexamethasone implant (Ozurdex) in the treatment of resistant diabetic macular edema. Journal of the Egyptian Ophthalmological Society. 2013. doi:10.4103/2090-0686.127404

BibTeX
@article{Salman2013,
  author = {Salman, AbdelrahmanG},
  title = {Long-term effect of intravitreal dexamethasone implant (Ozurdex) in the treatment of resistant diabetic macular edema},
  journal = {Journal of the Egyptian Ophthalmological Society},
  year = {2013},
  doi = {10.4103/2090-0686.127404}
}
Kostenlos starten →